The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect l-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats

Neuropharmacology

Volumn 58, Issue 2, 2010, Pages 528-536

  Mela, Flora ^a   Millan, Mark J ^b   Brocco, Mauricette ^b   Morari, Michele ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

D3 receptor; Drag test; Dyskinesia; l DOPA; Parkinson's disease; S33084

Indexed keywords

DOPAMINE 3 RECEPTOR BLOCKING AGENT; LEVODOPA; OXIDOPAMINE; S 33084; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DYSKINESIA; LONG TERM CARE; LOW DRUG DOSE; MALE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSONISM; PRIMARY PREVENTION; PRIORITY JOURNAL; RAT; ROTAROD TEST;

ANIMALS; ANTIPARKINSON AGENTS; BENZOPYRANS; DISABILITY EVALUATION; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; HYPOKINESIA; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D3; TIME FACTORS; TREATMENT OUTCOME;

EID: 72049118177     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.08.017     Document Type: Article

References (55)

1. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.H., Gauda E.B., Lee E.J., Cool M.H., Sibley D.R., Gerfen C.R., Westphal H., and Fuchs S. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. USA 93 (1997) 1945-1949
2. Andersson M., Hilbertson A., and Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6 (1999) 461-474
3. 3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J. Pharmacol. Exp. Ther. 287 (1998) 187-197
4. Barik S., and de Beaurepaire R. Evidence for a functional role of the dopamine D3 receptors in the cerebellum. Brain Res. 737 (1996) 347-350
5. Berthet A., Porras G., Doudnikoff E., Stark H., Cador M., Bezard E., and Bloch B. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of l-DOPA-induced dyskinesia. J. Neurosci. 29 (2009) 4829-4835
6. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., and Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 9 (2003) 762-767
7. 1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57 (2001) 1829-1834
8. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., and Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA 94 (1997) 3363-3367
9. Bordet R., Ridray S., Schwartz J.C., and Sokoloff P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur. J. Neurosci. 12 (2000) 2117-2123
10. Cenci M.A., Lee C.S., and Björklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10 (1998) 2694-2706
11. Cenci M.A. Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia. Trends Neurosci. 30 (2007) 236-243
12. Diaz J., Pilon C., Le Foll B., Gros C., Triller A., Schwartz J.C., and Sokoloff P. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 20 (2000) 8677-8684
13. 1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. 1158 (2007) 135-143
14. 3 receptor antisense to rat: effects on locomotion, dopamine release and [3H]spiperone binding. Naunyn Schmiedebergs Arch. Pharmacol. 358 (1998) 342-350
15. 3 receptor function and trafficking by heterodimerization. Mol. Pharmacol. 74 (2008) 59-69
16. 3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 572 (2007) 171-174
17. Gross C.E., Ravenscroft P., Dovero S., Jaber M., Bioulac B., and Bezard E. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J. Neurochem. 84 (2003) 1246-1255
18. Hattori S., Naoi M., and Nishino H. Striatal dopamine turnover during treadmill running in the rat: relation to the speed of running. Brain Res. Bull. 35 (1994) 41-49
19. Hurley M.J., Jolkkonen J., Stubbs C.M., Jenner P., and Marsden C.D. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res. 709 (1996) 259-264
20. 3 receptor agonists for protection and repair in Parkinson's disease. Curr. Opin. Pharmacol. 7 (2007) 100-105
21. Lane E.L., Cheetham S.C., and Jenner P. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?. Exp. Neurol. 197 (2006) 284-290
22. Loiseau F., and Millan M.J. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists. Eur. Neuropsychopharmacol. 19 (2009) 23-33
23. 2 dopamine receptors by nafadotride. Neuropsychopharmacology 17 (1997) 67-71
24. Lévesque D., Martres M.P., Diaz J., Griffon N., Lammers C.H., Sokoloff P., and Schwartz J.C. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. USA 92 (1995) 1719-1723
25. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15 (2002) 120-132
26. Marti M., Mela F., Fantin M., Zucchini S., Brown J.M., Witta J., Di Benedetto M., Buzas B., Reinscheid R.K., Salvadori S., Guerrini R., Romualdi P., Candeletti S., Simonato M., Cox B.M., and Morari M. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J. Neurosci. 25 (2005) 9591-9601
27. Marti M., Trapella C., Viaro R., and Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and l-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J. Neurosci. 27 (2007) 1297-1307
28. Mela F., Marti M., Dekundy A., Danysz W., Morari M., and Cenci M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem. 101 (2007) 483-497
29. Menalled L.B., Dziewczapolski G., Garcia M.C., Rubinstein M., and Gershanik O.S. D3 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion. Neuroreport 10 (1999) 3131-3136
30. Millan M.J., Dekeyne A., Rivet J.M., Dubuffet T., Lavielle G., and Brocco M. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293 (2000) 1063-1073
31. 3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293 (2000) 1048-1062
32. Millan M.J., Seguin L., Gobert A., Cussac D., and Brocco M. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology 174 (2004) 341-357
33. Millan M.J., Di Cara B., Dekeyne A., Panayi F., De Groote L., Sicard D., Cistarelli L., Billiras R., and Gobert A. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J. Neurochem. 100 (2007) 1047-1061
34. 2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J. Pharmacol. Exp. Ther. 324 (2008) 600-611
35. Monville C., Torres E.M., and Dunnett S.B. Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res. Bull. 68 (2005) 16-23
36. 3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 10 (1998) 2565-2573
37. 3) receptors: potential role of heterodimer formation. J. Neurochem. 102 (2007) 1410-1424
38. Obeso J.A., Olanow C.W., and Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23 10 Suppl (2000) S2-S7
39. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1982), Academic, Sidney
40. Papa S.M., Engber T.M., Kask A.M., and Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 662 (1994) 69-74
41. 3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol. Biochem. Behav. 86 (2007) 718-726
42. Quik M., Police S., He L., Di Monte D.A., and Langston J.W. Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 98 (2000) 263-273
43. Ridray S., Griffon N., Mignon V., Souil E., Carboni S., Diaz J., Schwartz J.C., and Sokoloff P. Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions. Eur. J. Neurosci. 10 (1998) 1676-1686
44. Rozas G., and Labandeira García J.L. Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Res. 749 (1997) 188-199
45. Sanberg P.R., Bunsey M.D., Giordano M., and Norman A.B. The catalepsy test: its ups and downs. Behav. Neurosci. 102 (1988) 748-759
46. 3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 275 (1995) 1239-1246
47. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., and Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 (2000) 777-787
48. 3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp. Neurol. 188 (2004) 128-138
49. 3) as a target for neuroleptics. Nature 347 (1990) 146-151
50. 3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets 5 (2006) 25-43
51. 3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience 116 (2003) 307-314
52. Visanji N.P., Millan M.J., and Brotchie J.M. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats. Exp. Neurol. 202 (2006) 85-92
53. Visanji N.P., Fox S.H., Johnston T., Reyes G., Millan M.J., and Brotchie J.M. Dopamine D(3) receptor stimulation underlies the development of l-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiol. Dis. 35 (2009) 184-192
54. Visanji N.P., Fox S.H., Johnston T.H., Millan M.J., and Brotchie J.M. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. J. Pharmacol. Exp. Ther. 328 (2009) 276-283
55. Westin J.E., Vercammen L., Strome E.M., Konradi C., and Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors Biol. Psychiatry 62 (2007) 800-810